CXCL8 and its cognate receptors in melanoma progression and metastasis.
The incidence of melanoma is rising at an alarming rate and we are still awaiting an effective treatment for this malignancy. In its early stage, melanoma can be cured by surgical removal, but once metastasis has occurred there is no effective treatment. Recent findings have suggested multiple functional implications of CXCL8 and its cognate receptors, CXCR1 and CXCR2, in melanoma pathogenesis, thus underscoring their importance as targets for cancer therapy. This review provides an update on the roles of CXCL8 and its receptors in melanoma progression and metastasis.
Singh
Seema
S
Department of Oncologic Sciences, Mitchell Cancer Institute, University of South Alabama, AL, USA.
Singh
Ajay P
AP
Sharma
Bhawna
B
Owen
Laurie B
LB
Singh
Rakesh K
RK
D000818:Animals; D018450:Disease Progression; D006801:Humans; D016209:Interleukin-8 / Q000378:metabolism*; D008545:Melanoma / Q000378:metabolism* / Q000473:pathology; D009362:Neoplasm Metastasis / Q000473:pathology; D023062:Receptors, Interleukin-8A / Q000378:metabolism*; D023063:Receptors, Interleukin-8B / Q000378:metabolism*; D012878:Skin Neoplasms / Q000378:metabolism* / Q000473:pathology
D016209:Interleukin-8; D023062:Receptors, Interleukin-8A; D023063:Receptors, Interleukin-8B